Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 16.05% is 20% below its 5-year average of 20.00%, near the low end of its 5-year range (10.98%–36.46%).
5.78% below its 12-month average of 17.04%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 8.92%.
RETURN ON ASSETS (ROA)
16.05%
RETURN ON ASSETS (ROA) AVG TTM
17.04%
RETURN ON ASSETS (ROA) AVG 3Y
15.32%
RETURN ON ASSETS (ROA) AVG 5Y
20.00%
RETURN ON ASSETS (ROA) AVG 10Y
4.00%
RETURN ON ASSETS (ROA) AVG 15Y
-12.96%
RETURN ON ASSETS (ROA) AVG 20Y
-22.21%
CURRENT VS TTM AVG
-5.78%
CURRENT VS 3Y AVG
+4.73%
CURRENT VS 5Y AVG
-19.76%
CURRENT VS 10Y AVG
+301.34%
CURRENT VS 15Y AVG
+223.87%
CURRENT VS 20Y AVG
+172.27%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+149.78%
vs the sector median at left
Halozyme Therapeutics, Inc.
Market Cap
$13.01B
Return on Assets (ROA)
16.05%
TTM Avg
17.04%
3Y Avg
15.32%
5Y Avg
20.00%
Market Cap
$12.93B
Return on Assets (ROA)
6.18%
TTM Avg
14.27%
3Y Avg
15.75%
5Y Avg
18.01%
Market Cap
$13.11B
Return on Assets (ROA)
-57.20%
TTM Avg
-68.10%
3Y Avg
-82.79%
5Y Avg
-75.08%
Market Cap
$12.61B
Return on Assets (ROA)
-10.75%
TTM Avg
-43.49%
3Y Avg
-42.71%
5Y Avg
-41.26%
Market Cap
$12.59B
Return on Assets (ROA)
-5.37%
TTM Avg
-3.64%
3Y Avg
-1.62%
5Y Avg
0.47%
Market Cap
$12.51B
Return on Assets (ROA)
4.91%
TTM Avg
1.34%
3Y Avg
-0.28%
5Y Avg
0.04%
Market Cap
$12.49B
Return on Assets (ROA)
8.13%
TTM Avg
5.32%
3Y Avg
4.08%
5Y Avg
2.47%
Market Cap
$12.38B
Return on Assets (ROA)
2.01%
TTM Avg
3.05%
3Y Avg
3.16%
5Y Avg
3.84%
Market Cap
$12.37B
Return on Assets (ROA)
8.33%
TTM Avg
7.48%
3Y Avg
6.38%
5Y Avg
5.99%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Halozyme Therapeutics, Inc. (HALO) | $13.01B | 16.05% | 17.04% | 15.32% | 20.00% |
| Corcept Therapeutics Incorporated (CORT)vs › | $12.93B | 6.18% | 14.27% | 15.75% | 18.01% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $13.11B | -57.20% | -68.10% | -82.79% | -75.08% |
| Tempus AI, Inc. (TEM)vs › | $12.61B | -10.75% | -43.49% | -42.71% | -41.26% |
| Baxter International Inc. (BAX)vs › | $12.59B | -5.37% | -3.64% | -1.62% | 0.47% |
| BrightSpring Health Services, Inc. Common Stock (BTSG)vs › | $12.51B | 4.91% | 1.34% | -0.28% | 0.04% |
| Penumbra, Inc. (PEN)vs › | $12.49B | 8.13% | 5.32% | 4.08% | 2.47% |
| ICON Public Limited Company (ICLR)vs › | $12.38B | 2.01% | 3.05% | 3.16% | 3.84% |
| Encompass Health Corporation (EHC)vs › | $12.37B | 8.33% | 7.48% | 6.38% | 5.99% |
| Summit Therapeutics Inc. (SMMT)vs › | $13.81B | -113.81% | -122.22% | -139.21% | -114.33% |
ROA
16.1%
ROE
288.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 12.55% |
| 2024-12-31 | 21.52% |
| 2023-12-31 | 16.25% |
| 2022-12-31 | 10.98% |
| 2021-12-31 | 36.46% |
| 2020-12-31 | 22.26% |
| 2019-12-31 | -12.77% |
| 2018-12-31 | -18.25% |
| 2017-12-31 | 12.11% |
| 2016-12-31 | -39.39% |
| 2015-12-31 | -17.73% |
| 2014-12-31 | -41.20% |
| 2013-12-31 | -82.01% |
| 2012-12-31 | -39.75% |
| 2011-12-31 | -30.06% |
| 2010-12-31 | -58.29% |
| 2009-12-31 | -75.65% |
| 2008-12-31 | -63.55% |
| 2007-12-31 | -23.10% |
| 2006-12-31 | -32.01% |
| 2005-12-31 | -64.73% |
| 2004-12-31 | -55.42% |
| 2003-12-31 | -166.45% |
| 2002-12-31 | -67.11% |
| 2001-12-31 | -151.77% |
